Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A

Vaccine

Volumn 33, Issue 48, 2015, Pages 6800-6808

  Stylianou, E ^a   Griffiths, K L ^a   Poyntz, H C ^a   Harrington Kandt, R ^a   Dicks, M D ^a   Stockdale, L ^a   Betts, G ^a   McShane, H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

BCG; Immunogenicity; Intranasal; Protection; Tuberculosis; Vaccine; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; BCG VACCINE; CHIMPANZEE ADENOVIRUS VECTOR; INTERLEUKIN 17; INTERLEUKIN 2; MODIFIED VACCINIA VIRUS ANKARA VECTOR; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM ANTIGEN AG85A; POXVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTIGEN 85A, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; DRUG CARRIER; LIVE VACCINE; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG POTENCY; FEMALE; IMMUNOGENICITY; LUNG ALVEOLUS CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; SIMIAN VIRUS; TREATMENT OUTCOME; TUBERCULOSIS; VACCINIA VIRUS;

ACYLTRANSFERASES; ADENOVIRUSES, SIMIAN; ANIMALS; ANTIGENS, BACTERIAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; IMMUNIZATION SCHEDULE; MICE, INBRED BALB C; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84949894912     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.017     Document Type: Article

References (39)

1. WHO Global Tuberculosis Report 2014 2014, Available from: http://www.who.int/tb/publications/global_report/en/.
2. Rodrigues L.C., Diwan V.K., Wheeler J.G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993, 22(6):1154-1158.
3. Andersen P., Kaufmann S.H. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med 2014, 4(6).
4. Grode L., Ganoza C.A., Brohm C., Weiner J., Eisele B., Kaufmann S.H. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 2013, 31(9):1340-1348.
5. Arbues A., Aguilo J.I., Gonzalo-Asensio J., Marinova D., Uranga S., Puentes E., et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine 2013, 31(42):4867-4873.
6. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17(2):189-194.
7. Day C.L., Tameris M., Mansoor N., van Rooyen M., de Kock M., Geldenhuys H., et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013, 188(4):492-502.
8. Aagaard C., Hoang T.T., Izzo A., Billeskov R., Troudt J., Arnett K., et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS ONE 2009, 4(6):pe5930.
9. Bertholet S., Ireton G.C., Ordway D.J., Windish H.P., Pine S.O., Kahn M., et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010, 2(53):53ra74.
10. Aeras. Vaccine candidates. Available from: http://www.aeras.org/candidates.
11. Ndiaye B.P., Thienemann F., Ota M., Landry B.S., Camara M., Dieye S., et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2015, 3:190-200.
12. Churchyard G.J., Snowden M.A., Hokey D., Dheenadhayalan V., McClain J.B., Douoguih M., et al. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4 T cell counts >350cells/mm. Vaccine 2015, 8:1890-1896.
13. Smaill F., Jeyanathan M., Smieja M., Medina M.F., Thanthrige-Don N., Zganiacz A., et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013, 5(205):205ra134.
14. Manjaly Thomas Z.R., McShane H. Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg 2015, 109(3):175-181.
15. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173(10):6357-6365.
16. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003, 171(3):1602-1609.
17. Satti I., Meyer J., Harris S.A., Manjaly Thomas Z.R., Griffiths K., Antrobus R.D., et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis 2014, 14(10):939-946.
18. Dicks M.D., Spencer A.J., Edwards N.J., Wadell G., Bojang K., Gilbert S.C., et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 2012, 7(7):pe40385.
19. Tatsis N., Tesema L., Robinson E.R., Giles-Davis W., McCoy K., Gao G.P., et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 2006, 13(5):421-429.
20. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 2006, 12(10):1596-1599.
21. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905.
22. Dudareva M., Andrews L., Gilbert S.C., Bejon P., Marsh K., Mwacharo J., et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 2009, 27(27):3501-3504.
23. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Isaacs F., et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010, 40(1):279-290.
24. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010, 181(12):1407-1417.
25. Dicks M.D., Guzman E., Spencer A.J., Gilbert S.C., Charleston B., Hill A.V., et al. The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Vaccine 2015, 33(9):1121-1128.
26. Farina S.F., Gao G.P., Xiang Z.Q., Rux J.J., Burnett R.M., Alvira M.R., et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001, 75(23):11603-11613.
27. Santosuosso M., McCormick S., Zhang X., Zganiacz A., Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006, 74(8):4634-4643.
28. Ronan E.O., Lee L.N., Beverley P.C., Tchilian E.Z. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS ONE 2009, 4(12):pe8235.
29. Saini D., Hopkins G.W., Chen C.J., Seay S.A., Click E.M., Lee S., et al. Sampling port for real-time analysis of bioaerosol in whole body exposure system for animal aerosol model development. J Pharmacol Toxicol Methods 2011, 63(2):143-149.
30. Thomas R.J. Particle size and pathogenicity in the respiratory tract. Virulence 2013, 4(8):847-858.
31. Xing Z., McFarland C.T., Sallenave J.M., Izzo A., Wang J., McMurray D.N. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE 2009, 4(6):pe5856.
32. Betts G., Poyntz H., Stylianou E., Reyes-Sandoval A., Cottingham M., Hill A., et al. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. PLoS ONE 2012, 7(12):pe50447.
33. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205(5):772-781.
34. de Barra E., Hodgson S.H., Ewer K.J., Bliss C.M., Hennigan K., Collins A., et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLOS ONE 2014, 9(12):pe115161.
35. Orme I.M. The Achilles heel of BCG. Tuberculosis (Edinb) 2010, 90(6):329-332.
36. Henao-Tamayo M., Ordway D.J., Orme I.M. Memory T cell subsets in tuberculosis: what should we be targeting?. Tuberculosis (Edinb) 2014, 94(5):455-461.
37. Lai R., Afkhami S., Haddadi S., Jeyanathan M., Xing Z. Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments. Eur Respir Rev 2015, 24(136):356-360.
38. Antrobus R.D., Coughlan L., Berthoud T.K., Dicks M.D., Hill A.V., Lambe T., et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther 2014, 22(3):668-674.
39. Ewer K.J., O'Hara G.A., Duncan C.J., Collins K.A., Sheehy S.H., Reyes-Sandoval A., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4:p2836.